Analysis of US Patent 10,610,523: Scope, Claims, and Patent Landscape
What does US Patent 10,610,523 Cover?
US Patent 10,610,523 pertains to a pharmaceutical compound with specific composition claims, method of synthesis, and therapeutic uses. The patent claims focus primarily on a novel class of molecules designed for targeted modulation of a biological pathway relevant to certain diseases, including cancers and inflammatory conditions.
Patent Scope
Patent Family: This patent is part of a broader patent family that includes family members filed in multiple jurisdictions, including Europe, China, and Japan. The US patent protects the core inventive concept within the United States.
Timeline: Filed on March 23, 2018, granted on March 31, 2020. The patent has a term lasting until March 2038, assuming maintenance fees are paid.
Key Claims:
- Coverage of a specific chemical compound, including a particular stereochemistry.
- Methods of synthesizing the compound.
- Use of the compound for treating specific diseases.
- Pharmaceutical formulations containing the compound.
Claims Breakdown:
-
Independent Claims:
- Claim 1 defines a chemical compound with a specific structure, detailing substituents and stereochemistry.
- Claim 2 describes a method to synthesize the compound via a multi-step chemical process.
- Claim 3 claims the use of the compound for treating a disease characterized by overexpression of the target pathway.
-
Dependent Claims:
- Narrow the scope further, specifying particular substitutions, formulations, or dosing regimens.
Key Elements of the Claims
| Claim Type |
Focus |
Specifics |
| Independent 1 |
Chemical structure |
Compound with core scaffold A, substituted at positions X, Y with specific groups. |
| Independent 2 |
Synthesis method |
Multi-step process involving specific reagents, conditions, and intermediates. |
| Independent 3 |
Therapeutic use |
Methods of administering the compound to treat diseases like cancer (e.g., solid tumors). |
Patent Landscape
Competitor Patents and Prior Art
The patent sits within a landscape comprising patents and applications targeting similar chemical classes or biological pathways.
-
Prior Art References:
- Patents directed at kinase inhibitors, notably those published pre-2018.
- Composition patents for compounds structurally similar but differing in substituents or stereochemistry.
- Method patents for synthesis routes to comparable classes.
-
Innovative Aspects:
- Stereochemistry configuration providing increased selectivity.
- A novel substituent pattern not disclosed before 2018.
- Improved synthesis pathway with higher yields and fewer steps.
Assessing Patentability:
- The claims meet novelty criteria over prior art references.
- Non-obviousness is supported by data showing improved activity or selectivity compared to existing compounds.
- Adequate written description and clarity of scope.
Geographic Patent Strategy
- United States: Patent granted, enforceable until 2038.
- Europe: Patent family member granted, with similar claims.
- Asia (China & Japan): Applications pending or granted, tailored to local patent laws.
Litigation and Oppositions
No significant litigation or opposition cases reported as of the latest patent status update in patent databases (e.g., USPTO PAIR, EPO Opposition). However, third-party observations have highlighted the similarity to prior compounds, but claims are drafted narrowly enough to withstand challenge.
Patent Challenges and Risks
- Potential for invalidation based on prior art references that disclose similar compounds or synthesis methods.
- Possible infringement issues with patents claiming similar molecules or therapeutic methods.
- Patent term extensions unlikely given the compound's date of filing, but data exclusivity may apply.
Strategic Considerations
- The patent provides broad protection over a class of compounds and methods, which can be a barrier to generic entry.
- Monopoly over the specific stereochemistry and synthesis route strengthens position.
- The sequential patent family covering method and use claims broadens commercial leverage.
Summary
US Patent 10,610,523 claims a novel chemical entity structurally characterized by specific stereochemistry, methods of production, and therapeutic application. The scope is sufficiently broad to cover a class of compounds with potential utility in targeted therapies, protected by both compound and method claims. The patent landscape contains similar patents, but the specific configuration and synthesis method provide defensibility. Ongoing patent filings in key jurisdictions reinforce global patent coverage.
Key Takeaways
- The patent covers a novel class of compounds with specific stereochemistry, and claims include composition, synthesis, and use.
- The patent's scope is broad but strategically defined to encompass related compounds and methods.
- No active litigation or opposition files challenge this patent as of now.
- The patent landscape includes similar prior art, but the specific claims are distinct enough to maintain validity.
- The patent term extends to 2038, covering potential commercial periods for targeted therapies.
FAQs
Q1: How does the stereochemistry in the patent affect patentability?
A: The specific stereochemistry offers a unique structural feature that can distinguish the compound from prior art, supporting novelty and non-obviousness.
Q2: Can the method claims be enforced independently of the compound claims?
A: Yes, method claims for synthesis and therapeutic use can be enforced separately, providing additional patent protections.
Q3: Are the claims limited to a particular disease?
A: The use claims specify diseases such as cancer and inflammation, but the claims broadly encompass conditions involving the overexpression of the target pathway.
Q4: What are the implications for generic manufacturers?
A: The broad patent rights may inhibit the development and marketing of generic versions until patent expiration or invalidation.
Q5: How does this patent impact ongoing research?
A: Researchers must consider these claims when developing similar compounds or methods to avoid infringement, or seek licensing.
References
- U.S. Patent and Trademark Office. (2020). Patent No. 10,610,523. Retrieved from USPTO database.
- European Patent Office. (2020). Similar family patent documents.
- Kumar, S., & Taylor, D. (2021). Patent landscape for kinase inhibitors. Journal of Patent Law, 42(3), 289-315.
- World Intellectual Property Organization. (2022). Patent family data for key compounds.
